Rodríguez, Albert TucaViejo, Miguel NúñezMaradey, PabloCanal-Sotelo, JaumeMancilla, Plácido GuardiaRivero, Sonia GutiérrezCasillas, Inmaculada RajaAbián, María HerreraBermudo, Cristina López2023-05-032023-05-032022-02-09http://hdl.handle.net/10668/20494Aim: This subanalysis of the CAVIDIOPAL study evaluated the impact of individualized management of breakthrough cancer pain (BTcP) with fentanyl on the quality of life (QoL) of advanced cancer patients in Spanish palliative care units. Patients & methods: This was a prospective, observational, multicenter study. The European Organization for Research and Treatment of Cancer's QLQ-C30 questionnaire was used at baseline (V0) and visit 28 (V28). Results: Ninety-five patients were mainly treated with 67-133 μg fentanyl, showing a notable reduction in intensity (visual analog scale: 8.0 [V0] to 4.6 [V28]), frequency and duration of BTcP episodes shortly after the first 1-2 weeks of treatment, with significantly improved QoL (global health status: 31.1 [V0] to 53.1 [V28]). Conclusion: Low-dose sublingual fentanyl effectively reduced BTcP in advanced cancer patients in palliative care units, significantly improving QoL. Clinical trial registration: NCT02840500 (ClinicalTrials.gov).enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/breakthrough cancer painpain managementpalliative carequality of lifetransmucosal fentanylAnalgesics, OpioidBreakthrough PainCancer PainFentanylHumansNeoplasmsPalliative CareProspective StudiesQuality of Liferesearch article35137627open access10.2217/fon-2021-16391744-8301https://doi.org/10.2217/fon-2021-1639